KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares Outstanding
Ratios

Biogen (BIIB) Leases (2016 - 2026)

Biogen has reported Leases over the past 18 years, most recently at $251.3 million for Q1 2026.

  • For Q1 2026, Leases fell 27.45% year-over-year to $251.3 million; the TTM value through Mar 2026 reached $251.3 million, down 27.45%, while the annual FY2025 figure was $265.4 million, 25.53% down from the prior year.
  • Leases for Q1 2026 was $251.3 million at Biogen, down from $265.4 million in the prior quarter.
  • Over five years, Leases peaked at $460.9 million in Q3 2023 and troughed at $251.3 million in Q1 2026.
  • A 5-year average of $366.9 million and a median of $366.5 million in 2023 define the central range for Leases.
  • Biggest five-year swings in Leases: grew 14.14% in 2023 and later decreased 27.45% in 2026.
  • Year by year, Leases stood at $403.9 million in 2022, then grew by 3.99% to $420.0 million in 2023, then fell by 15.14% to $356.4 million in 2024, then fell by 25.53% to $265.4 million in 2025, then decreased by 5.31% to $251.3 million in 2026.
  • Business Quant data shows Leases for BIIB at $251.3 million in Q1 2026, $265.4 million in Q4 2025, and $330.5 million in Q3 2025.